Biotech Company News

IntraBio Receives Niemann-Pick disease European Orphan Drug Designation for IB1000 Series

IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare "orphan" and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation for its lead compound series (IB1000s) for the treatment Niemann-Pick disease Type A, B and C. Niemann-Pick disease Type C (NPC) is a rare, devastating, neurovisceral autosomal-recessive inherited metabolic, lysosomal storage disorder (LSD) that predominately affects pediatric patients. Niemann-Pick disease Type C affects
Biotechnology Clinical Trials Pharmaceuticals Prescriptions Prodrug

IU Research Suggests Failed Osteoarthritis Drug Could Get New Life as Opioid-Addiction Treatment

A new study from Indiana University suggests that a drug proven safe for use in people may prevent opioid tolerance and physical dependence when used in combination with opioid-based pain medications. Researchers in the Linda and Jack Gill Center for Biomolecular Science at IU Bloomington have discovered that a compound previously tested to treat osteoarthritis pain appears to block neuropathic pain and decrease signs of opioid dependence. The work is reported in the